<p>马萨诸塞州剑桥市和蒙特利尔 --（商业新闻）--Repare Therapeutics Inc.（“Repare” 或 “公司”）（纳斯达克：RPTX），一家临床阶段的精准肿瘤学公司，今天宣布与吉利德科学公司达成了一项最终资产购买协议，以收购 Repare 的聚合酶θ（Polθ）ATP 酶抑制剂 RP-3467（“吉利德协议”）。</p>
<p>“我们很高兴宣布这一交易，它将吉利德在肿瘤研究和开发方面的领先专业知识与 RP-3467 这一潜在的最佳 Polθ ATP 酶抑制剂结合在一起，” Repare 的总裁、首席执行官兼首席财务官 Steve Forte 表示。“这标志着 Repare 今年第三笔也是最重要的投资组合交易。”</p>
<p>根据吉利德协议的条款，Repare 将获得高达 3000 万美元的总对价，其中包括 2500 万美元的预付款，受制于惯例的扣留和调整，以及在完成特定技术转让活动后额外支付的 500 万美元。</p>
<p>2025 年 11 月 14 日，Repare 宣布已与 XenoTherapeutics, Inc.和 Xeno Acquisition Corp.（统称 “Xeno”）达成了一项最终安排协议（“安排协议”），根据该协议，Xeno 将收购 Repare 所有已发行和流通的普通股（“普通股”）（“安排交易”）。根据安排协议的条款，Repare 的股东将根据安排交易结束时 Repare 的现金余额（“安排结束时的现金净额”）在扣除某些交易成本和未偿还负债的总额后，获得每股普通股的现金支付。</p>
<p>根据吉利德协议下应支付的对价的预付款部分，Repare 的现金余额有所增加，因此，预计的安排结束时的现金净额也有所增加。根据 Repare 对安排结束时现金净额的修订估计，目前预计每位 Repare 股东将在安排结束时获得约 2.20 美元的现金支付。</p>
<p><strong>关于 RP-3467。</strong></p>
<p>RP-3467 是一种高效的小分子 Polθ抑制剂，是与 BRCA 突变和其他基因组改变相关的合成致死靶点。RP-3467 正在 POLAR I 期临床试验中评估其安全性、药代动力学、药效学及其单独或与奥拉帕利联合使用在局部晚期或转移性上皮卵巢癌、转移性乳腺癌、转移性去势抵抗性前列腺癌或胰腺腺癌患者中的初步活性。</p>
<p><strong>关于 Repare Therapeutics Inc.</strong></p>
<p>Repare Therapeutics 是一家临床阶段的精准肿瘤学公司，利用其专有的合成致死方法发现和开发新型治疗药物。Repare Therapeutics 开发了高度靶向的癌症疗法，专注于基因组不稳定性，包括 DNA 损伤修复。有关更多信息，请访问 www.reparerx.com，并在 X（前身为 Twitter）和 LinkedIn 上关注 @Reparerx。</p>
<p><strong>附加信息及获取途径</strong></p>
<p>公司已向截至 2025 年 11 月 21 日（“记录日期”）的股东提交了一份最终代理声明（Schedule 14A），以及其他与拟议交易相关的文件。代理声明包含有关与 Xeno 拟议交易及相关事项的重要信息，包括关于公司将于 2026 年 1 月 16 日举行的股东特别会议的信息，会议上将寻求股东对该交易的必要批准。<strong>公司投资者和证券持有者被敦促仔细阅读整个代理声明（包括任何修订或补充），因为其中包含有关与 Xeno 拟议交易及特别会议上将投票事项的重要信息。</strong></p>
<p>公司投资者和证券持有者可以免费获取代理声明的副本，以及其他相关文件，这些文件包含有关公司及拟议交易的信息，包括将被纳入代理声明的材料，均可在证券交易委员会（“SEC”）的网站（http://www.sec.gov）上获取，或通过联系公司的投资者关系部门（电话：857-412-7018），在公司网站（https://www.reparerx.com/contact/）提交联系表，或访问公司网站的投资者关系页面（https://ir.reparerx.com/investor-relations），点击标题为 “SEC Filings” 的链接。</p>
<p><strong>征求意见的参与者</strong></p>
<p>公司及其某些董事、高级管理人员和员工可能被视为在与 Xeno 交易中向公司股东征集代理权的 “参与者”。有关公司董事和高级管理人员的身份信息，以及他们在公司证券中的直接和间接利益（通过证券持有或其他方式）已在 2025 年 12 月 12 日向美国证券交易委员会（SEC）提交的 14A 号正式代理声明中列出。有关公司董事和高级管理人员持有公司证券的后续变动信息可以在公司网站 www.reparerx.com 或 SEC 网站 www.sec.gov 上的 3、4 和 5 号表格中找到。有关代理征集参与者的身份以及他们在与 Xeno 交易中的直接和间接利益（通过证券持有或其他方式）的描述包含在与 Xeno 交易相关的代理声明及其他相关材料中，这些材料已向 SEC 提交。可以从 SEC 或公司免费获取这些文件，具体信息如前段所述。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》和加拿大证券法定义的 “前瞻性声明”。本新闻稿中除历史事实陈述外的所有陈述均为 “前瞻性声明”。这些声明可能通过诸如 “旨在”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“打算”、“可能”、“计划”、“可能的”、“潜在的”、“寻求”、“将会” 等词语及其变体或类似表达来识别，尽管并非所有前瞻性声明都包含这些词语。本新闻稿中的前瞻性声明包括但不限于关于：公司与吉利德的交易，包括根据资产购买协议条款收到未来付款的情况及交易的潜在利益；公司与 Xeno 的交易，包括与 Xeno 安排关闭时的现金净额、预计公司股东在安排关闭时收到的现金支付以及关于特别会议的声明；RP-3467 的潜在治疗益处；以及 POLAR 1 期临床试验的进展和结果。这些前瞻性声明基于公司截至本新闻稿日期的预期和假设。每一项前瞻性声明都涉及风险和不确定性，可能导致公司的临床开发计划、未来结果或表现与前瞻性声明中表达或暗示的内容有实质性差异。许多因素可能导致当前预期与实际结果之间的差异，包括：公司成功追求具有吸引力条款的战略交易的能力，或根本无法实现；在临床前测试和早期临床试验中的成功并不确保后续临床试验会产生相同结果或提供足够的数据以证明产品候选者的有效性和安全性；宏观经济条件的影响，包括关税和其他贸易政策、乌克兰冲突和中东冲突、通货膨胀波动以及不确定的信贷和金融市场对公司的业务、临床试验和财务状况的影响；在临床前研究或临床试验中观察到的意外安全性或有效性数据；临床试验现场激活或入组率低于预期；公司实现其合作和许可协议利益的能力；预期或现有竞争的变化；监管环境的变化；监管批准过程的不确定性和时机；以及意外的诉讼或其他争议。本新闻稿中前瞻性声明所表达或暗示的实际结果可能与公司在 2024 年 12 月 31 日结束的年度报告（Form 10-K）中 “风险因素” 部分以及不时向 SEC 和 AMF 提交的其他文件中识别的因素有所不同。公司明确声明不承担更新本声明中包含的任何前瞻性声明的义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有要求的情况除外。有关更多信息，请访问 reparerx.com，并在 X（前 Twitter）上关注 Repare，账号为 @RepareRx，以及在 LinkedIn 上访问 https://www.linkedin.com/company/repare-therapeutics/。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ4MDA4ODZyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ4MDA4ODZyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251224800886/en/</p>
<p><strong>投资者关系与媒体：</strong></p>
<p>Matthew DeYoung</p>
<p>投资者关系与媒体</p>
<p>Argot Partners</p>
<p>investor@reparerx.com</p>
<p>来源：Repare Therapeutics Inc.</p>

吉利德科学

RPTX

<p>Repare Therapeutics 宣布其 Polθ ATPase 抑制剂 RP-3467 被吉利德科学收购，交易金额最高可达 3000 万美元。该交易包括 2500 万美元的预付款和 500 万美元的技术转让完成后的付款。此外，Repare 与 XenoTherapeutics 签署了一项安排协议，以收购其所有普通股，股东根据修订后的现金余额每股获得约 2.20 美元</p>

<p>CAMBRIDGE, Mass. &amp; MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”).</p>
<div class="lb-trans"><p>马萨诸塞州剑桥市和蒙特利尔 --（商业新闻）--Repare Therapeutics Inc.（“Repare” 或 “公司”）（纳斯达克：RPTX），一家临床阶段的精准肿瘤学公司，今天宣布与吉利德科学公司达成了一项最终资产购买协议，以收购 Repare 的聚合酶θ（Polθ）ATP 酶抑制剂 RP-3467（“吉利德协议”）。</p>
</div><p>“We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class Polθ ATPase inhibitor,” said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. “This marks the third and most significant portfolio transaction for Repare this year.”</p>
<div class="lb-trans"><p>“我们很高兴宣布这一交易，它将吉利德在肿瘤研究和开发方面的领先专业知识与 RP-3467 这一潜在的最佳 Polθ ATP 酶抑制剂结合在一起，” Repare 的总裁、首席执行官兼首席财务官 Steve Forte 表示。“这标志着 Repare 今年第三笔也是最重要的投资组合交易。”</p>
</div><p>Under the terms of the Gilead Agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment, subject to customary holdbacks and adjustments, and an additional $5 million payment upon completion of specified technology transfer activities.</p>
<div class="lb-trans"><p>根据吉利德协议的条款，Repare 将获得高达 3000 万美元的总对价，其中包括 2500 万美元的预付款，受制于惯例的扣留和调整，以及在完成特定技术转让活动后额外支付的 500 万美元。</p>
</div><p>On November 14, 2025, Repare announced that it had entered into a definitive arrangement agreement (the “Arrangement Agreement”) with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), pursuant to which Xeno will acquire (the “Arrangement Transaction”) all of the issued and outstanding common shares of Repare (the “Common Shares”). Under the terms of the Arrangement Agreement, Repare shareholders will receive a cash payment per Common Share that will be determined based upon Repare’s cash balance at closing of the Arrangement Transaction (the “Arrangement Closing”) after deducting certain transaction costs and the aggregate amount of outstanding liabilities (the “Closing Net Cash Amount”).</p>
<div class="lb-trans"><p>2025 年 11 月 14 日，Repare 宣布已与 XenoTherapeutics, Inc.和 Xeno Acquisition Corp.（统称 “Xeno”）达成了一项最终安排协议（“安排协议”），根据该协议，Xeno 将收购 Repare 所有已发行和流通的普通股（“普通股”）（“安排交易”）。根据安排协议的条款，Repare 的股东将根据安排交易结束时 Repare 的现金余额（“安排结束时的现金净额”）在扣除某些交易成本和未偿还负债的总额后，获得每股普通股的现金支付。</p>
</div><p>The upfront portion of the consideration payable under the Gilead Agreement has increased Repare’s cash balance and, therefore, has also increased the estimated Closing Net Cash Amount. Based on Repare’s revised estimate of the Closing Net Cash Amount, it is now currently estimated that each Repare shareholder will receive a cash payment of approximately US$2.20 per Common Share at the Arrangement Closing.</p>
<div class="lb-trans"><p>根据吉利德协议下应支付的对价的预付款部分，Repare 的现金余额有所增加，因此，预计的安排结束时的现金净额也有所增加。根据 Repare 对安排结束时现金净额的修订估计，目前预计每位 Repare 股东将在安排结束时获得约 2.20 美元的现金支付。</p>
</div><p><strong>About RP-3467.</strong></p>
<div class="lb-trans"><p><strong>关于 RP-3467。</strong></p>
</div><p>RP-3467 is a highly potent, small molecule inhibitor of Polθ that is a synthetic lethality target associated with BRCA mutations and other genomic alterations. RP-3467 is being evaluated in the POLAR Phase 1 clinical trial to evaluate its safety, pharmacokinetics, pharmacodynamics and preliminary activity alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer or pancreatic adenocarcinoma.</p>
<div class="lb-trans"><p>RP-3467 是一种高效的小分子 Polθ抑制剂，是与 BRCA 突变和其他基因组改变相关的合成致死靶点。RP-3467 正在 POLAR I 期临床试验中评估其安全性、药代动力学、药效学及其单独或与奥拉帕利联合使用在局部晚期或转移性上皮卵巢癌、转移性乳腺癌、转移性去势抵抗性前列腺癌或胰腺腺癌患者中的初步活性。</p>
</div><p><strong>About Repare Therapeutics Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Repare Therapeutics Inc.</strong></p>
</div><p>Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn.</p>
<div class="lb-trans"><p>Repare Therapeutics 是一家临床阶段的精准肿瘤学公司，利用其专有的合成致死方法发现和开发新型治疗药物。Repare Therapeutics 开发了高度靶向的癌症疗法，专注于基因组不稳定性，包括 DNA 损伤修复。有关更多信息，请访问 www.reparerx.com，并在 X（前身为 Twitter）和 LinkedIn 上关注 @Reparerx。</p>
</div><p><strong>Additional Information and Where to Find It</strong></p>
<div class="lb-trans"><p><strong>附加信息及获取途径</strong></p>
</div><p>The Company has filed and furnished to its shareholders of record the close of business on November 21, 2025 (the “Record Date”) a definitive proxy statement on Schedule 14A, as well as other relevant documents concerning the proposed transaction with Xeno. The proxy statement contains important information about the proposed transaction with Xeno and related matters, including information related to a special meeting of Shareholders to be held on January 16, 2026 by the Company seeking required approvals from the shareholders in connection with such transaction. <strong>Investors and security holders of the Company are urged to carefully read the entire proxy statement (including any amendments or supplements thereto) because it contains important information about the proposed transaction with Xeno and the matters to be voted on at the special meeting.</strong></p>
<div class="lb-trans"><p>公司已向截至 2025 年 11 月 21 日（“记录日期”）的股东提交了一份最终代理声明（Schedule 14A），以及其他与拟议交易相关的文件。代理声明包含有关与 Xeno 拟议交易及相关事项的重要信息，包括关于公司将于 2026 年 1 月 16 日举行的股东特别会议的信息，会议上将寻求股东对该交易的必要批准。<strong>公司投资者和证券持有者被敦促仔细阅读整个代理声明（包括任何修订或补充），因为其中包含有关与 Xeno 拟议交易及特别会议上将投票事项的重要信息。</strong></p>
</div><p>Investors and security holders of the Company are able to obtain a free copy of the proxy statement, as well as other relevant filings containing information about the Company and the proposed transaction, including materials that will be incorporated by reference into the proxy statement, without charge, at the Securities and Exchange Commission’s (“SEC”) website (http://www.sec.gov) or from the Company by contacting the Company’s Investor Relations at (857) 412-7018, by submitting a contact form on the Company’s website at https://www.reparerx.com/contact/, or by going to the Company’s Investor Relations page on its website at https://ir.reparerx.com/investor-relations and clicking on the link titled “SEC Filings.”</p>
<div class="lb-trans"><p>公司投资者和证券持有者可以免费获取代理声明的副本，以及其他相关文件，这些文件包含有关公司及拟议交易的信息，包括将被纳入代理声明的材料，均可在证券交易委员会（“SEC”）的网站（http://www.sec.gov）上获取，或通过联系公司的投资者关系部门（电话：857-412-7018），在公司网站（https://www.reparerx.com/contact/）提交联系表，或访问公司网站的投资者关系页面（https://ir.reparerx.com/investor-relations），点击标题为 “SEC Filings” 的链接。</p>
</div><p><strong>Participants in the Solicitation</strong></p>
<div class="lb-trans"><p><strong>征求意见的参与者</strong></p>
</div><p>The Company and certain of its directors, executive officers and employees may be deemed to be “participants” in the solicitation of proxies from the Company’s shareholders with respect to the transaction with Xeno. Information regarding the identity of the Company’s directors and executive officers, and their direct and indirect interests, by security holdings or otherwise, in the Company’s securities is set forth in the definitive proxy statement on Schedule 14A filed with the SEC on December 12, 2025. Information regarding subsequent changes to the holdings of the Company’s securities by the Company’s directors and executive officers can be found in filings on Forms 3, 4, and 5, which are available on the Company’s website at www.reparerx.com or through the SEC’s website at www.sec.gov. Additional information regarding the identity of the participants in the proxy solicitation and a description of their direct and indirect interests in the transaction with Xeno, by security holdings or otherwise, is contained in the proxy statement and other relevant materials filed with the SEC in connection with the transaction with Xeno. Copies of these documents may be obtained, free of charge, from the SEC or the Company as described in the preceding paragraph.</p>
<div class="lb-trans"><p>公司及其某些董事、高级管理人员和员工可能被视为在与 Xeno 交易中向公司股东征集代理权的 “参与者”。有关公司董事和高级管理人员的身份信息，以及他们在公司证券中的直接和间接利益（通过证券持有或其他方式）已在 2025 年 12 月 12 日向美国证券交易委员会（SEC）提交的 14A 号正式代理声明中列出。有关公司董事和高级管理人员持有公司证券的后续变动信息可以在公司网站 www.reparerx.com 或 SEC 网站 www.sec.gov 上的 3、4 和 5 号表格中找到。有关代理征集参与者的身份以及他们在与 Xeno 交易中的直接和间接利益（通过证券持有或其他方式）的描述包含在与 Xeno 交易相关的代理声明及其他相关材料中，这些材料已向 SEC 提交。可以从 SEC 或公司免费获取这些文件，具体信息如前段所述。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company’s transaction with Gilead, including the receipt of the future payments under the terms of the asset purchase agreement and the potential benefits of the transaction; the Company’s transaction with Xeno, including the Closing Net Cash at the closing of the arrangement with Xeno, the expected cash payment to be received by Company’s shareholders at the Arrangement Closing and statements regarding the special meeting; the potential therapeutic benefits of RP-3467; and the progress and results of the POLAR Phase 1 clinical trial. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s ability to successfully pursue a strategic transaction on attractive terms, or at all; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) and the Québec Autorité des Marchés Financiers (“AMF”) on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit reparerx.com and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at https://www.linkedin.com/company/repare-therapeutics/.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》和加拿大证券法定义的 “前瞻性声明”。本新闻稿中除历史事实陈述外的所有陈述均为 “前瞻性声明”。这些声明可能通过诸如 “旨在”、“预期”、“相信”、“可能”、“估计”、“期望”、“预测”、“目标”、“打算”、“可能”、“计划”、“可能的”、“潜在的”、“寻求”、“将会” 等词语及其变体或类似表达来识别，尽管并非所有前瞻性声明都包含这些词语。本新闻稿中的前瞻性声明包括但不限于关于：公司与吉利德的交易，包括根据资产购买协议条款收到未来付款的情况及交易的潜在利益；公司与 Xeno 的交易，包括与 Xeno 安排关闭时的现金净额、预计公司股东在安排关闭时收到的现金支付以及关于特别会议的声明；RP-3467 的潜在治疗益处；以及 POLAR 1 期临床试验的进展和结果。这些前瞻性声明基于公司截至本新闻稿日期的预期和假设。每一项前瞻性声明都涉及风险和不确定性，可能导致公司的临床开发计划、未来结果或表现与前瞻性声明中表达或暗示的内容有实质性差异。许多因素可能导致当前预期与实际结果之间的差异，包括：公司成功追求具有吸引力条款的战略交易的能力，或根本无法实现；在临床前测试和早期临床试验中的成功并不确保后续临床试验会产生相同结果或提供足够的数据以证明产品候选者的有效性和安全性；宏观经济条件的影响，包括关税和其他贸易政策、乌克兰冲突和中东冲突、通货膨胀波动以及不确定的信贷和金融市场对公司的业务、临床试验和财务状况的影响；在临床前研究或临床试验中观察到的意外安全性或有效性数据；临床试验现场激活或入组率低于预期；公司实现其合作和许可协议利益的能力；预期或现有竞争的变化；监管环境的变化；监管批准过程的不确定性和时机；以及意外的诉讼或其他争议。本新闻稿中前瞻性声明所表达或暗示的实际结果可能与公司在 2024 年 12 月 31 日结束的年度报告（Form 10-K）中 “风险因素” 部分以及不时向 SEC 和 AMF 提交的其他文件中识别的因素有所不同。公司明确声明不承担更新本声明中包含的任何前瞻性声明的义务，无论是由于任何新信息、未来事件、情况变化或其他原因，法律另有要求的情况除外。有关更多信息，请访问 reparerx.com，并在 X（前 Twitter）上关注 Repare，账号为 @RepareRx，以及在 LinkedIn 上访问 https://www.linkedin.com/company/repare-therapeutics/。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjQ4MDA4ODZyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251224800886r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251224800886/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251224800886/en/</p>
</div><p><strong>Investor Relations &amp; Media:</strong></p>
<div class="lb-trans"><p><strong>投资者关系与媒体：</strong></p>
</div><p>Matthew DeYoung</p>
<div class="lb-trans"><p>Matthew DeYoung</p>
</div><p>Investor Relations and Media</p>
<div class="lb-trans"><p>投资者关系与媒体</p>
</div><p>Argot Partners</p>
<div class="lb-trans"><p>Argot Partners</p>
</div><p>investor@reparerx.com</p>
<div class="lb-trans"><p>investor@reparerx.com</p>
</div><p>Source: Repare Therapeutics Inc.</p>
<div class="lb-trans"><p>来源：Repare Therapeutics Inc.</p>
</div>

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration | RPTX Stock News

Repare Therapeutics 宣布吉利德科学以总对价最高达 3000 万美元收购 Polθ ATPase 抑制剂 RP-3467 | RPTX 股票新闻